To enhance the usefulness of splenic perfusion evaluated by means of dynamic computed tomography (CT) and spleen size in assessing the degree of liver fibrosis.
INTRODUCTION

I
T IS USEFUL to assess the degree of liver fibrosis before making decisions or predicting disease outcomes in chronic liver disease. 1, 2 Liver fibrosis can currently be evaluated without biopsy using serum fibrosis markers and liver elastography. 1, 3 However, under certain conditions these methods produce divergent results, and biopsy becomes necessary. 3 Finding another non-invasive method will reduce this necessity.
To some extent, the amount of splenic perfusion indicates the degree of liver fibrosis. It has been shown by means of the maximum slope method that normal spleens and spleens associated with liver cirrhosis display different amounts of perfusion. [4] [5] [6] Sauter et al. 7 reported that, by means of compartment model analysis, mean transit time (MTT) was longer in spleens with cirrhosis than in normal spleens. However, there have been no studies comparing splenic perfusion among patients with various intermediate stages of liver fibrosis. Thus, the usefulness of splenic perfusion in assessing the degree of liver fibrosis has not been elucidated.
Splenomegaly is often used radiologically as an indicator of cirrhosis. It has been shown that portal venous pressure positively correlates with spleen size. [8] [9] [10] [11] [12] Therefore, we evaluated the usefulness of splenic perfusion and spleen size in assessing the degree of liver fibrosis. The aim of this study was to pinpoint the extent to which splenic perfusion indicates the degree of liver fibrosis and to enhance the usefulness of splenic perfusion, evaluated by means of dynamic computed tomography (CT), and of spleen size, in assessing the degree of liver fibrosis.
METHODS
Patient characteristics
T HIS RETROSPECTIVE STUDY was approved by our Institutional Review Board, and written informed consent was obtained. Patient characteristics are shown in Table 1 . We listed 136 consecutive patients from 2008 to 2013 who had undergone multiphasic i.v. contrastenhanced dynamic CT within 30 days before hepatectomy. Makuuchi's criteria 13 were used in determining whether each patient should undergo hepatectomy. Fibrosis was histologically established in all of the patients by means of surgical samples; we extracted the stage of fibrosis described in the pathological reports. Three of the 136 patients were excluded from this study, two because they had undergone splenectomies, and one because the aorta was too small in diameter (region of interest [ROI] 
Computed tomography protocol
The protocol of dynamic contrast-enhanced CT is shown in Table 2 . We used a 64-row CT scanner, the Light Speed VCT (GE Healthcare, Little Chalfont, UK). Pre-contrast phase and nine phases after i.v. contrast agent injection were scanned: seven at 6-s intervals beginning at 22 s after injection, and one each at 90 and 210 s after injection. Scan parameters were as follows: the range was caudal 25 cm from the upper level of the diaphragm; tube voltage, 120 kVp; tube current, 300 mA (2nd through 8th, and . A non-ionic iodinated contrast agent (Iopamiron 370 mg/mL; Bayer Healthcare, Berlin, Germany) was given i.v. through a 22-gauge catheter in the median cubital vein. The total dose was 100 mL, and the rate of injection was 3 mL/s. This CT protocol was adopted instead of angiography, CT during arterioportography, or CT during hepatic arteriography, for preoperative mapping of vascular anatomy and detection of small lesions.
Image analysis and statistics
Two radiologists (T.S. and A.Y.), with 2 and 16 years of experience, respectively, set ROIs in consensus as large as possible, located at the spleen [C s (t)] and at the aorta [C a (t)] in the same slice, as shown in Figure 1 , and obtained time-attenuation data generated from the ROIs. The radiologists are among the authors, but they set the ROIs without knowing the degree of fibrosis in each patient. The minimum area of the ROIs was restricted to 300 mm 2 at the spleen and 200 mm 2 at the aorta. The concentration of iodine was directly proportional to the CT value, 14 and changes in the CT value in the target organ were expressed by the differential equation -117 ), respectively. The Kruskal-Wallis test revealed that there were significant differences in K 1 (P < 0.01), MTT (P < 0.001), and R (P < 0.0001), depending on the stage of liver fibrosis. V d did not significantly depend on the stage of fibrosis (P = 0.11). Multiple comparisons showed significant differences (P < 0.05) between K 1 at F0 and at F4, between K 1 at F2 and at F4, between MTT at F0 and at F4, between MTT at F1 and at F4, between MTT at F2 and at F4, between R at F0 and at F4, and between R at F1 and at F4, as Figure 2 shows.
Stepwise regression analysis showed that, of the perfusion parameters, spleen size, age, gender, MTT, R, and the presence or absence of HBV and/or HCV infection were the significant explanatory variables, as Figure 3 
DISCUSSION
O UR RESULTS INDICATED that K 1 and V d did not determine the stage of fibrosis statistically. The MTT in patients with cirrhosis tended to be longer than in patients with earlier stages of fibrosis. R values in patients with intermediate fibrosis tended to be longer than in patients without fibrosis. V d is the apparent volume in which the contrast agent is potentially distributed throughout the extracellular space and is expressed as the product of MTT and K 1 . It was shown that MTT tended to increase and K 1 tended to decrease as a progression of liver fibrosis, so the product V d was constant and did not depend on the degree of fibrosis. That is, we believe that the apparent volume did not change and that blood inflow/outflow velocity decreased. In other words, the microstructures of the spleen did not change extensively in the progression of liver fibrosis, and hemodynamic change (decreasing blood inflow/outflow velocity) was more noteworthy.
The diagnostic accuracy of the combination of MTT, R, and the presence or absence of HBV infection, and that of HCV infection, in detecting liver fibrosis was as follows: AUROC (95% confidence interval) = 0.828 (0.825-0.830) for ≥F2; and 0.819 (0.817-0.822) for F4. This is not less than that of currently used non-invasive methods such as transient erastography 15 (AUROC = 0.78 for ≥F2; 0.89 for F4) and serum biomarkers 16 (AUROC = 0.73 for ≥F2; 0.90 for F4).
Serum fibrosis markers and liver elastography are, alone or in combination, among the most accurate non-invasive examinations for assessing the degree of liver fibrosis. Indeed, these methods are highly accurate and good for fibrosis staging. However, they are less available than dynamic CT and insufficient for screening HCC or detecting complications of portal hypertension, whereas dynamic CT is widely available and sufficient for these purposes. If, in addition, dynamic CT can provide information about the degree of liver fibrosis, it is even more useful than currently thought.
There are several studies on assessing the degree of liver fibrosis using CT perfusion of the liver. 17, 18 However, the assessment of liver perfusion using pharmacokinetic models requires more data and higher temporal resolution, because the liver has two sources of blood (the portal vein and the hepatic artery), whereas the spleen has only one (the splenic artery). Although splenic perfusion indicates liver fibrosis only indirectly, the assessment of splenic perfusion requires less data and lower temporal resolution than the assessment of liver perfusion. Thus, splenic perfusion is easier to use than liver perfusion.
According to Ronot et al., 18 MTT of the liver increases in early stages of fibrosis. Our study showed that MTT of the spleen increases in later stages of fibrosis. This may be because the liver cannot expand as the spleen does in order to compensate for portal hypertension.
Our CT protocol was for preoperative evaluation of hepatic lesions and liver vascular anatomy as well as for perfusion analysis by a 64-row detector CT scanner, so the temporal resolution in our CT protocol was lower than in usual perfusion imaging. [19] [20] [21] [22] However, it was high enough to evaluate the differences among patients with different stages of liver fibrosis. This is mainly because the pharmacokinetic model of the spleen is simpler than that of the liver for evaluating perfusion parameters, as explained above.
Increased MTT of the spleen in cirrhosis may reflect dynamic changes in the spleen and in splenic hemodynamics. It has been reported that the amount of fluid extravasation from splenic circulation increases as an adaptation to portal hypertension. 23 One of the main causes of portal hypertension is hyperdynamic circulation. 9, [24] [25] [26] Once hyperdynamic circulation occurs, portal pressure increases dramatically. 27 It has been said that excessive systemic nitric oxide (NO) production may cause increases in splanchnic blood flow and in angiogenesis during hyperdynamic circulation. 28 Exactly when hyperdynamic circulation starts in the progression of liver fibrosis is not known. Morales-Ruiz et al. 29 showed that NO synthase was elevated in rats with cirrhosis and ascites, and Noguchi et al. 30 showed that there was no elevation of serum NO in patients with F4 who were classified as Child-Pugh A and had undergone hepatectomy. Therefore, hyperdynamic circulation may start between early and advanced cirrhosis. Accordingly, increased MTT of the spleen in cirrhosis may reflect the increase in fluid extravasation from splenic circulation after hyperdynamic circulation.
Splenic blood flow increases as a progression of portal hypertension. The spleen enlarges to compensate for portal hypertension and to maintain a constant splenic blood flow; MTT of the spleen does not change. However, the spleen cannot enlarge indefinitely because of anatomical limitations, so extravasation in the spleen occurs in order to compensate for the portal hypertension; MTT becomes longer in cirrhosis.
This study has several limitations. First, as the spleen is heterogeneously enhanced in the arterial phases, it would have been ideal to measure the whole spleen. Unfortunately, it was not practical to do so. We attempted to compensate for this by setting the ROI of the spleen as large as possible. Second, we did not have enough samples to assess the difference in splenic perfusion between patients with porto-systemic collateral vessels and those without. All of the patients in our study had undergone hepatectomy, and there were few patients with these vessels, because patients with severe cirrhosis who had developed shunts were mostly rejected for hepatectomy in preoperative consideration. Third, our surgical samples do not represent the whole liver. However, they represent a larger portion of the liver than the current gold standard biopsy does. Finally, several studies have shown that the appropriate amount of contrast agent varies with body weight. 20, 31 We were constrained by the available data, in which the protocol was for preoperative evaluation of vascular anatomy and therefore emphasized vascular visualization (at least 600 mg I/kg is recommended as a total dose of contrast agent). 32, 33 The densest contrast agent and 100 mL dosage were adopted for purposes of preoperative evaluation.
In conclusion, the combination of spleen size and MTT, one of the pharmacokinetic parameters of splenic perfusion evaluated by means of dynamic CT, is helpful in assessing the degree of liver fibrosis.
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